| Literature DB >> 33406488 |
Daniel A Pollyea1, Dale Bixby2, Alexander Perl3, Vijaya Raj Bhatt4, Jessica K Altman5, Frederick R Appelbaum6, Marcos de Lima7, Amir T Fathi8, James M Foran9, Ivana Gojo10, Aric C Hall11, Meagan Jacoby12, Jeffrey Lancet13, Gabriel Mannis14, Guido Marcucci15, Michael G Martin16, Alice Mims17, Jadee Neff18, Reza Nejati19, Rebecca Olin20, Mary-Elizabeth Percival6, Thomas Prebet21, Amanda Przespolewski22, Dinesh Rao23, Farhad Ravandi-Kashani24, Paul J Shami25, Richard M Stone26, Stephen A Strickland27, Kendra Sweet13, Pankit Vachhani28, Matthew Wieduwilt29, Kristina M Gregory30, Ndiya Ogba30, Martin S Tallman31.
Abstract
The NCCN Guidelines for Acute Myeloid Leukemia (AML) provide recommendations for the diagnosis and treatment of adults with AML based on clinical trials that have led to significant improvements in treatment, or have yielded new information regarding factors with prognostic importance, and are intended to aid physicians with clinical decision-making. These NCCN Guidelines Insights focus on recent select updates to the NCCN Guidelines, including familial genetic alterations in AML, postinduction or postremission treatment strategies in low-risk acute promyelocytic leukemia or favorable-risk AML, principles surrounding the use of venetoclax-based therapies, and considerations for patients who prefer not to receive blood transfusions during treatment.Entities:
Mesh：
Year: 2021 PMID： 33406488 DOI： 10.6004/jnccn.2021.0002
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908